DGX - Quest Diagnostics Incorporated (DGX) Q1 2024 Earnings Call Transcript
2024-04-23 12:31:02 ET
Quest Diagnostics Incorporated (DGX)
Q1 2024 Earnings Conference Call
April 23, 2024 08:30 a.m. ET
Company Participants
Jim Davis - Chairman, Chief Executive Officer, President
Sam Samad - Chief Financial Officer
Shawn Bevec - Vice President of Investor Relations
Conference Call Participants
Patrick Donnelly - Citi
Ann Hynes - Mizuho Securities
Kevin Caliendo - UBS
Taji Phillips - Jefferies
Erin Wright - Morgan Stanley
Michael Cherny - Leerink Partners
Jack Meehan - Nephron Research
Elizabeth Anderson - Evercore ISI
Lisa Gill - J.P. Morgan
Michael Ryskin - Bank of America
Stephanie Davis - Barclays
Andrew Brackmann - William Blair
Presentation
Operator
Welcome to the Quest Diagnostics First Quarter 2024 Conference Call. At the request of the company, this call is being recorded. The entire contents of the call, including the presentation and question-and-answer session that will follow, are the copyrighted property of Quest Diagnostics with all rights reserved. Any redistribution, retransmission or rebroadcast of this call in any form without the written consent of Quest Diagnostics is strictly prohibited.
Now I’d like to introduce Shawn Bevec, Vice President of Investor Relations for Quest Diagnostics. Sir, please go ahead.
Shawn Bevec
Thank you, and good morning. I'm joined by Jim Davis, our Chairman, Chief Executive Officer and President; and Sam Samad, our Chief Financial Officer. During this call, we may make forward-looking statements and will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release.
Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K.
For this call, references to reported EPS refer to reported diluted EPS and references to adjusted EPS refer to adjusted diluted EPS. Any references to base business, testing, revenues or volumes refer to the performance of our business excluding COVID-19 testing.
Growth rates associated with our long-term outlook projections, including consolidated revenue growth, revenue growth from acquisitions, organic revenue growth and adjusted earnings growth are compound annual growth rates. Finally, revenue growth rates from acquisitions will be measured against our base business....
Quest Diagnostics Incorporated (DGX) Q1 2024 Earnings Call Transcript